Hannah Chang, M.D., Ph.D.

Callio Therapeutics is pioneering the next generation of antibody-drug conjugates with a pipeline of dual-payload ADCs designed to overcome treatment resistance and drive deeper, more durable responses. While first-generation ADCs have transformed cancer treatment, most patients ultimately progress and have urgent need for better therapies. Powered by highly adaptable dual-payload technology, backed by top life science investors, and led by an experienced team with a track record of success, Callio Therapeutics is built to deliver better outcomes for patients.

Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in allergic disease treatment. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a unique triple-action design currently being studied in atopic diseases. Poplar is pursuing the bold idea that IgE can be rapidly driven toward zero, with the goal of helping people with IgE-mediated conditions move from fear toward freedom.

Hearing Restored.

Perfuse Therapeutics is a clinical-stage biopharmaceutical company committed to reducing the incidence of blindness. Our mission is to develop novel therapeutics to protect and improve the vision of patients with ocular diseases.

At PACT Pharma, our vision is to create potentially curative T cell therapies for solid cancers that are tailored for each and every patient. We are pioneering non-viral, precision-genome engineered, tumor-specific T-cell therapies for cancer patients because we envision a world where everyone has access to personalized treatment regardless of who they are and where they come from. We currently focus on treating solid tumors. PACT Pharma believes that the only way forward is together, and we look for individuals to join our team who share our values. Teamwork and humility are highly prized. So is speaking with kindness. Be ready to share your ideas, because we create a culture that listens to ideas and isn’t afraid to implement them. If you have a passion for turning ideas into realities and seek a work environment where your colleagues are equally engaged and enthusiastic, you’ll want to join us. If you desire a stimulating fast-paced environment, working with intelligent people who are making an impact in cancer, you will want to join the PACT Pharma team. We are a rapidly expanding, innovative, and collaborative workforce working towards one main goal, eradicating cancer! We are in the San Francisco bay area, the heart of the world’s premier biotechnology research hub. PACT Pharma offers a competitive compensation and benefits package, including participation in the aggressive growth of the company in the form of stock option grants.

Semma Therapeutics is pioneering the new treatment paradigm of using cells as medicine. Semma’s new class of regenerative medicine therapies couples its breakthrough stem cell technologies with proprietary delivery systems designed to protect cells from the immune system. Ongoing research at Semma Therapeutics is focused on combining these highly-differentiated active cells with a state-of-the-art device to provide a functional cure for patients with diabetes. Semma Therapeutics is working to bring new therapeutic options to the clinic and improve the lives of patients. The company is headquartered in Cambridge, MA, with operations in Providence, RI. For more information, visit www.semma-tx.com.

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.

Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. There is a growing body of evidence around inhibiting VCP to target cancer stress pathways with known biological relevance in cancer. Cleave has ongoing collaborations with the National Cancer Institute (NCI) and leading academic institutions. The company is leveraging this combined expertise to advance VCP/p97 inhibitors for cancer and neurodegenerative disease. VCP is a critical enzyme in the AAA (ATPases Associated with diverse cellular Activities) family of ATPases and is a key regulator of various aspects of protein homeostasis and cellular stress that are critical for cancer cell growth and survival. In neurodegenerative diseases, VCP/p97 has been shown to be important for the health and function of mitochondria, and Cleave’s research has demonstrated the potential for therapeutic benefit for patients with limited treatment options with those devastating diseases. Cleave’s oncology drug discovery pipeline exploits molecular features that are dependent on VCP/p97 and are key to the growth and survival of cancers cells. Cleave’s lead drug development candidate, CB-5339, is a potent, oral, selective, second-generation inhibitor of VCP/p97, which addresses the limitations of earlier compounds, including exposure and selectivity to the target. The company is launching a Phase 1 clinical study in acute myeloid leukemia (AML), for which there is compelling preclinical data and a significant unmet medical need. The National Cancer Institute has a decades long interest in VCP/p97 as a target and is planning to sponsor a Phase I trial with CB-5339 in solid tumors.

BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop new small molecule therapeutics against challenging, high-value drug targets.

Callio Therapeutics is pioneering the next generation of antibody-drug conjugates with a pipeline of dual-payload ADCs designed to overcome treatment resistance and drive deeper, more durable responses. While first-generation ADCs have transformed cancer treatment, most patients ultimately progress and have urgent need for better therapies. Powered by highly adaptable dual-payload technology, backed by top life science investors, and led by an experienced team with a track record of success, Callio Therapeutics is built to deliver better outcomes for patients.

Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in allergic disease treatment. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a unique triple-action design currently being studied in atopic diseases. Poplar is pursuing the bold idea that IgE can be rapidly driven toward zero, with the goal of helping people with IgE-mediated conditions move from fear toward freedom.

Hearing Restored.

Perfuse Therapeutics is a clinical-stage biopharmaceutical company committed to reducing the incidence of blindness. Our mission is to develop novel therapeutics to protect and improve the vision of patients with ocular diseases.